Loading...
XKRX
253840
Market cap39mUSD
Jul 10, Last price  
3,815.00KRW
1D
5.39%
1Q
-17.16%
IPO
-41.31%
Name

SugenTech Inc

Chart & Performance

D1W1MN
XKRX:253840 chart
P/E
P/S
6.61
EPS
Div Yield, %
Shrs. gr., 5y
3.68%
Rev. gr., 5y
-25.62%
Revenues
9.42b
-6.74%
601,109,6181,090,268,1623,439,993,3035,448,790,0673,845,080,64641,351,848,29877,201,041,000101,399,256,0007,132,306,00010,097,083,0009,416,858,000
Net income
-23.31b
L+53.46%
-1,511,996,258-1,558,392,021-20,960,485,413-40,915,428,995-9,561,056,493-41,018,413,35936,151,559,00026,716,631,000-17,238,284,000-15,192,705,000-23,314,481,000
CFO
-14.65b
L+94.85%
-1,197,283,537-1,335,399,006-909,594,013-3,134,053,492-4,011,329,34614,571,522,49038,955,129,00030,427,995,000-12,153,245,000-7,517,117,000-14,646,930,409
Dividend
Dec 27, 2023150 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sugentech Inc., a South Korean firm, develops and markets advanced in-vitro diagnostic (IVD) systems and products worldwide. Their solutions integrate biotechnology, information technology, and nanotechnology. The company's diverse portfolio features sophisticated Multiplex BLOT disease diagnostic platforms, including automated immunoblot processors and molecular diagnostic tools, alongside various test kits. They also offer a range of convenient self-testing products, such as digital ovulation, pregnancy, and early pregnancy detection kits, as well as mobile testing options. Additionally, Sugentech provides point-of-care (POC) analyzers and tests for a broad spectrum of conditions, from infectious diseases like M.tuberculosis, M.bovis, SARS-CoV-2 (antibodies and antigens), and influenza A/B, to critical biomarkers such as CRP/hsCRP/dualCRP, procalcitonin, troponin I, hemoglobinA1c, and human chorionic gonadotropin. Founded in 2011, the company, originally named Accugen Healthcare, Inc., adopted its current name, Sugentech Inc., in October 2013 and is headquartered in Daejeon.
IPO date
Nov 11, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT